These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11306264)

  • 1. Promising clinical trials on kinase inhibitor.
    de Boer J
    Trends Cell Biol; 2001 Mar; 11(3):110. PubMed ID: 11306264
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
    Mahon FX
    Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
    Yamaguchi M; Konishi I
    Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.
    Sakamoto E; Sawada T; Osugi H; Nakamae H; Koh KR; Yamane T; Ohsawa M; Wakasa K; Hino M
    Int J Hematol; 2008 Oct; 88(3):348-350. PubMed ID: 18758897
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
    Chrobák L; Voglová J
    Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.
    Holyoake DT
    Br J Haematol; 2001 Apr; 113(1):11-23. PubMed ID: 11328274
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 10. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA
    J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST1571: a paradigm for clinical trials of molecularly targeted agents.
    Druker BJ
    Biomed Pharmacother; 2001 Nov; 55(9-10):529-30. PubMed ID: 11769961
    [No Abstract]   [Full Text] [Related]  

  • 14. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
    O'Dwyer ME; Druker BJ
    Curr Opin Oncol; 2000 Nov; 12(6):594-7. PubMed ID: 11085460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ
    J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract]   [Full Text] [Related]  

  • 17. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lower dose of imatinib to CML patients.
    Horikoshi A; Takei K; Sawada S
    Leuk Res; 2003 Dec; 27(12):1167. PubMed ID: 12921957
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
    Nimmanapalli R; Bhalla K
    Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.